Sodium Phosphate, Bowel Evacuant
Pronunciation: SOE-dee-um FOS-fate
Class: Bowel evacuant
- Tablets 1.5 g
- Tablets 1.5 g
Induces diarrhea through the osmotic effect of sodium, which causes large amounts of water to be drawn into the colon, promoting evacuation.
1 to 3 h.
Special PopulationsRenal Function Impairment
Elimination of the large phosphate load may be impaired. Use with caution.Hepatic Function Impairment
Pharmacokinetics have not been studied.Elderly
Plasma half-life is 2-fold higher in subjects older than 70 yr of age.Gender
No difference in AUC has been observed between healthy men and women.
Indications and Usage
Cleansing of the colon for colonoscopy.
Biopsy-proven acute phosphate nephropathy; known allergy to sodium phosphate salts or any component of the product.
Dosage and AdministrationAdults OsmoPrep
PO 48 g (32 tablets) of sodium phosphate with a total of 2 quarts of clear liquids taken as follows: On the evening prior to the colonoscopy procedure take 6 g (4 tablets) with 240 mL (8 oz) of clear liquid every 15 min for a total of 30 g (20 tablets). On the day of the colonoscopy procedure, starting 3 to 5 hours before the procedure, take 6 g (4 tablets) with 240 mL (8 oz) of clear liquid every 15 min for a total of 18 g (12 tablets).Visicol
PO 60 g (40 tablets) of sodium phosphate with a total of 3.6 quarts of clear liquids as follows: On the evening prior to the colonoscopy procedure take 4.5 g (3 tablets; the last dose will be 3 g [2 tablets]) with 240 mL (8 oz) of clear liquid every 15 min for a total of 30 g (20 tablets). On the day of the colonoscopy procedure, starting 3 to 5 hours before the procedure, take 4.5 g (3 tablets; the last dose will be 3 g [2 tablets]) with 240 mL (8 oz) of clear liquid every 15 min for a total of 30 g (20 tablets).
- Patients should be adequately hydrated before, during, and after the use of sodium phosphate.
- Patients should not use OsmoPrep or Visicol for colon cleansing within 7 days of previous administration.
- Patients should not take additional agents (eg, enemas, laxatives), particularly those containing sodium phosphate.
Store at 59° to 86°F. Discard any unused portion.
Drug InteractionsCoadministered medications
Medications administered in close proximity may not be absorbed from the GI tract because of rapid intestinal peristalsis. Use with caution in patients taking medications known to prolong the QT interval.
Laboratory Test Interactions
None well documented.
Dizziness, headache, seizures (postmarketing).
Bloating (47%); nausea (37%); abdominal pain (30%); vomiting (10%); aphthous ulcers (3%).
Acute phosphate nephropathy, acute renal failure, nephrocalcinosis, renal impairment, renal tubular necrosis (postmarketing).
Hypersensitivity reactions including anaphylaxis, bronchospasm, dysphagia, dyspnea, paresthesia, pharyngeal edema, pruritus, rash, throat tightness, urticaria, and swelling of the face, lips, and tongue (postmarketing).
Hyperphosphatemia (96%); hypocalcemia (47%); hypokalemia (28%); increased BUN, increased creatinine (postmarketing).
Rare but serious cases of acute phosphate nephropathy have been reported. Some cases have resulted in permanent renal function impairment. Some patients have required long-term dialysis. Risk factors may include increased age, hypovolemia, increased bowel transit time, active colitis or baseline kidney disease, and use of medications that affect renal perfusion or function (eg, diuretics, NSAIDs). However, some patients did not have identifiable risk factors.
Consider performing baseline and post-colonoscopy labs (phosphate, calcium, potassium, sodium, creatine, and BUN) in patients who are at increased risk of serious adverse reactions (eg, history of renal insufficiency, acute phosphate neuropathy, known or suspected electrolyte disorders, seizures, arrhythmias, prolonged QT, cardiomyopathy, recent MI). Measure postcolonoscopy labs in patients who develop vomiting and/or signs of dehydration. Consider pre-dose and post-colonoscopy ECGs in patients at risk of serious cardiac arrhythmias.
Category C .
Safety and efficacy not established.
Use with caution.
Special Risk Patients
Use with caution in patients with severe renal insufficiency (CrCl less than 30 mL/min), CHF, ascites, unstable angina, gastric retention, ileus, acute bowel obstruction, pseudo-obstruction of the bowel, severe chronic constipation, bowel perforation, acute colitis, toxic megacolon, gastric bypass or stabling surgery, hypermotility syndrome, or recent cardiac surgery.
Adequate hydration before, during, and after use is important. Fatalities due to fluid shifts, severe electrolyte abnormalities, and cardiac arrhythmias have occurred. These fatalities occurred in patients with renal insufficiency or bowel perforation, and in patients who misused or overdosed with sodium phosphate.
Inflammatory bowel disease
Use with caution; sodium phosphate absorption may be enhanced.
Renal failure and acute phosphate nephropathy may occur.
Generalized tonic-clonic seizures and/or loss of consciousness have been reported.
Severe electrolyte disturbances, including cardiac arrhythmias, death, dehydration, hypernatremia, hyperphosphatemia, hypocalcemia, hypokalemia, hypovolemia, renal failure, seizures.
- Instruct patients to take product exactly as prescribed.
- Inform patients that it is important to take the recommended fluid regimen to assist in adequate hydration.
- Instruct patients not to use OsmoPrep or Visicol for colon cleansing within 7 days of previous administration.
- Instruct patients not take additional laxative or purgative agents, particularly those containing sodium phosphate.
- Instruct patients to drink 240 mL (8 oz) of clear liquid with each dose of the sodium phosphate product.
- Instruct patients to tell health care provider if they have any of the following symptoms while taking the sodium phosphate product: bloating, dizziness, headache, less than normal urination, nausea, severe stomach cramping, trouble drinking clear fluids, or vomiting.
- Instruct patients to immediately contact their health care provider if they take too much sodium phosphate product.
- Inform patient that undigested or partially digested tablets may be seen in the stool.
Copyright © 2009 Wolters Kluwer Health.